What is silent myocardial ischemia?

It is a condition in which episodes of myocardial ischemia occur in the absence of chest pain or other classic symptoms, often detected by instrumental examinations.

Who is most at risk for silent ischemia?

Diabetic patients, the elderly, subjects with autonomic neuropathy or a history of ischemic heart disease.

How is silent myocardial ischemia diagnosed?

By 24-hour Holter ECG, exercise testing, stress echocardiography, myocardial scintigraphy or cardiac MRI, even in the absence of symptoms.

What is the most effective treatment?

Lifestyle modifications, targeted drug therapy (beta-blockers, statins, antiplatelets) and, in selected cases, coronary revascularization.

What is the prognosis?

If unrecognized, it is associated with a high risk of infarction and complications; optimal management reduces cardiovascular mortality.

L'angolo del dottorino

Change Language:

Index

Search the site... Advanced search

✖

Silent Myocardial Ischemia

Article written and reviewed by Dr Luca Moretti

Silent myocardial ischemia is a condition characterized by the occurrence of ischemic episodes in the myocardium without anginal symptoms. It is often diagnosed incidentally by instrumental examinations, as patients do not experience chest pain or other obvious clinical signs.
The underlying mechanism is a transient reduction in coronary blood flow, generally secondary to atherosclerotic plaques, microcirculatory alterations, or endothelial dysfunction.
The lack of pain perception can be attributed to an elevated pain threshold or a reduced neurovegetative response of the myocardium.

Epidemiology and Risk Factors

Silent ischemia is particularly frequent in patients with diabetes mellitus, in whom autonomic neuropathy can impair the perception of chest pain. It is also common in the elderly and in those with previous ischemic heart disease.

The main risk factors include:

Diabetes mellitus: Autonomic neuropathy alters the perception of ischemic pain.
Arterial hypertension: Promotes endothelial dysfunction and arterial stiffness.
Dyslipidemia: LDL deposition in the vessel walls promotes atherosclerosis.
Cigarette smoking: Induces a pro-inflammatory and pro-thrombotic state.
Obesity and sedentary lifestyle: Worsen the metabolic profile and increase cardiovascular risk.
History of myocardial infarction: Residual ischemia may manifest in a silent manner.

Diagnosis and Instrumental Investigations

Silent myocardial ischemia is often identified incidentally during diagnostic examinations performed for other reasons. The baseline ECG may be normal or show nonspecific ventricular repolarization abnormalities.
The most frequently used instrumental tests include:

24-hour Holter ECG: Allows detection of silent ischemia episodes with transient ST-segment depression.
Exercise test: May reveal ischemic changes in the absence of anginal symptoms.
Stress echocardiography: Identifies segmental wall motion abnormalities under stress.
Myocardial perfusion scintigraphy: Distinguishes between reversible perfusion defects (ischemia) and fixed defects (previous infarction).
Cardiac Magnetic Resonance with Stress: Detects inducible ischemia using vasodilator drugs or dobutamine.
Coronary angiography: Essential in cases with a high suspicion of significant coronary artery disease.

Treatment of Silent Myocardial Ischemia

The treatment aims to reduce the risk of cardiovascular events and improve myocardial perfusion.

Lifestyle modifications:
Adopting healthy habits is essential. Smoking cessation, a balanced diet, and regular physical activity reduce the risk of progression of atherosclerotic disease.

Pharmacological therapy:

Beta-blockers and calcium-channel blockers: Reduce myocardial oxygen demand.
Statins: Control atherosclerosis and stabilize the plaque.
Antiplatelet agents: Prevent thrombotic events (aspirin, clopidogrel).
ACE inhibitors or sartans: Useful in patients with hypertension or left ventricular dysfunction.

Myocardial revascularization:
In patients with documented extensive ischemia, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) may be indicated according to the severity of coronary artery disease.

Prognosis and Complications

Silent myocardial ischemia is associated with an increased risk of myocardial infarction, ventricular arrhythmias, and ischemic heart failure, making timely diagnosis and appropriate therapeutic management crucial.

References

Chaitman BR, et al. Silent myocardial ischemia and ischemic heart disease. J Am Coll Cardiol. 2002;39(11):1899-905.
Fihn SD, et al. ACCF/AHA guidelines for stable ischemic heart disease. J Am Coll Cardiol. 2012;60(24):2564-603.
Montalescot G, et al. ESC guidelines on chronic coronary syndromes. Eur Heart J. 2019;41(3):407-477.
Shah SJ, et al. Microvascular dysfunction in ischemic heart disease. J Am Coll Cardiol. 2020;75(20):2534-48.
O’Donoghue ML, et al. Antiplatelet therapy in ischemic heart disease. Circ Res. 2020;126(4):492-504.
Greenland P, et al. Coronary artery calcium score and cardiovascular risk. JAMA. 2018;319(3):286-295.
Shah NR, et al. Advances in imaging for silent ischemia. Heart. 2018;104(3):213-222.
Task Force Members. ESC guidelines on cardiovascular prevention. Eur Heart J. 2021;42(34):3227-3337.
Patel MR, et al. Diagnostic approaches in coronary artery disease. J Am Coll Cardiol. 2020;76(3):231-245.
Fox K, et al. Management of stable coronary artery disease. BMJ. 2011;342:d3317.